Yu Shou-Chun, Shiue Yow-Ling, Wu Yu-Cih, Wang Jhi-Joung, Liao Kuang-Ming, Ho Chung-Han
Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
Department of Medical Research, Chi-Mei Medical Center, Chiali, Tainan, Taiwan.
Front Oncol. 2023 Apr 14;13:1139925. doi: 10.3389/fonc.2023.1139925. eCollection 2023.
The global incidence of early-onset colorectal cancer (EO-CRC) is increasing. Although the mortality rate is relatively stable, some comorbidities have been associated with a higher mortality rate. This study estimated the mortality risk in patients with EO-CRC with various comorbidities using real-world data to identify the high-risk group using Cox proportional regression for overall and cancer-specific mortality. The incidence rate of EO-CRC significantly increased from 6.04 per 100,000 population in 2007 to 12.97 per 100,000 population in 2017. The five-year overall mortality rate was 101.50 per 1000 person year and the cancer-specific mortality rate was 94.12 per 1000 person year. Patients with cerebrovascular disease (CVD) had a higher mortality risk (hazard ratio (HR): 1.68; 95% confidence interval (CI): 1.25-2.28; p=0.0007). After subgroup analyses based on age, sex, clinical stage, and treatment type, patients with CVD had a higher overall mortality risk compared to non-CVD patients, except for patients undergoing surgery and chemotherapy. Patients with chronic kidney disease had a higher mortality risk in the early clinical stages (HR: 2.31; 95% CI: 1.08-4.96; p=0.0138). Patients who underwent radiotherapy had a higher overall mortality risk (HR: 1.38; 95% CI: 1.04-1.85; p=0.0285) than those without liver disease. Identifying specific comorbidity mortality risks in patients with EO-CRC allows for risk stratification when screening target groups and may lower disease mortality.
早发性结直肠癌(EO-CRC)的全球发病率正在上升。尽管死亡率相对稳定,但一些合并症与较高的死亡率相关。本研究使用真实世界数据估计了患有各种合并症的EO-CRC患者的死亡风险,采用Cox比例回归分析总体死亡率和癌症特异性死亡率,以识别高危人群。EO-CRC的发病率从2007年的每10万人6.04例显著增加到2017年的每10万人12.97例。五年总体死亡率为每1000人年101.50例,癌症特异性死亡率为每1000人年94.12例。脑血管疾病(CVD)患者的死亡风险更高(风险比(HR):1.68;95%置信区间(CI):1.25-2.28;p=0.0007)。在根据年龄、性别、临床分期和治疗类型进行亚组分析后,除接受手术和化疗的患者外,CVD患者的总体死亡风险高于非CVD患者。慢性肾病患者在临床早期的死亡风险更高(HR:2.31;95%CI:1.08-4.96;p=0.0138)。接受放疗的患者的总体死亡风险(HR:1.38;95%CI:1.04-1.85;p=0.0285)高于未患肝病的患者。识别EO-CRC患者的特定合并症死亡风险有助于在筛查目标人群时进行风险分层,并可能降低疾病死亡率。